Business Context and Reporting Period
Company: PDS Biotechnology Corp (PDSB)
Filing Type: Form 8-K (Current Report)
Date of Report: August 11, 2026
Event: Regulation FD Disclosure regarding a letter to shareholders issued on August 11, 2026.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a disclosure of a shareholder communication rather than a financial statement.
Material Changes
No material financial changes or operational updates are detailed within the body of this 8-K filing. The document solely references the issuance of a shareholder letter (Exhibit 99.1).
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates by reference a letter to shareholders dated August 11, 2026, which is available on the company's Investor Relations website. The specific content of this letter, including any guidance or outlook, is not contained in the text of this 8-K.
Risks and Contingencies: The filing includes a standard disclaimer stating that the information in Item 7.01 and Exhibit 99.1 is furnished, not "filed," for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Review the full text of the Shareholder Letter (Exhibit 99.1) on the company's Investor Relations website for specific operational or financial details.
- Verify the trading status of Common Stock (PDSB) on The Nasdaq Stock Market LLC.
- Confirm the identity of the authorized signatory: Frank Bedu-Addo, Ph.D., President and CEO.